These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35149318)

  • 1. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
    Zheng B; Hudson M; Wang M; Baron M;
    Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis.
    Zheng B; Wang M; McKenna K; Shapiro L; Silver R; Csuka ME; van den Hoogen F; Robinson D; Pauling JD; Hummers L; Krieg T; Del Galdo F; Spiera R; Jones N; Khalidi N; Vacca A; de Vries-Bouwstra JK; Gordon J; Baron M;
    Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1806-1812. PubMed ID: 38662853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
    Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
    Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
    Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
    Khanna D; Huang S; Lin CJF; Spino C
    Ann Rheum Dis; 2021 May; 80(5):641-650. PubMed ID: 33257497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of the 2017 EUSTAR activity index in an scleroderma cohort.
    Ross L; Stevens W; Wilson M; Huq M; Strickland G; Walker J; Sahhar J; Ngian GS; Roddy J; Youssef P; Proudman S; Nikpour M
    Clin Rheumatol; 2020 Dec; 39(12):3701-3705. PubMed ID: 32696281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
    Spiera R; Kuwana M; Khanna D; Hummers L; Frech TM; Stevens W; Matucci-Cerinic M; Kafaja S; Distler O; Jun JB; Levy Y; Leszcyzński P; Gordon J; Steen V; Lee EB; Jankowski T; Litinsky I; Chung L; Hsu V; Mayes M; Sandorfi N; Simms RW; Finzel S; de Vries-Bouwstra J; Constantine S; Dgetluck N; Dinh Q; Bloom BJ; Furst DE; White B; Denton CP;
    Arthritis Rheumatol; 2023 Sep; 75(9):1608-1618. PubMed ID: 37098795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
    Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
    Arthritis Care Res (Hoboken); 2016 Feb; 68(2):167-78. PubMed ID: 26806474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid skin thickness progression rate is associated with high incidence rate of cardiopulmonary complications in patients with early diffuse cutaneous systemic sclerosis: inception cohort study.
    Wangkaew S; Thongwitokomarn H; Prasertwittayakij N; Euathrongchit J
    Clin Exp Rheumatol; 2020; 38 Suppl 125(3):98-105. PubMed ID: 32865165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
    Spiera R; Khanna D; Kuwana M; Furst DE; Frech TM; Hummers L; Stevens W; Matucci-Cerinic M; Baron M; Distler O; Dgetluck N; Bloom BJ; Dinh Q; White B; Denton CP
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):124-133. PubMed ID: 34323681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
    Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of sensitivity to change of the European Scleroderma Study Group activity index.
    Melsens K; De Keyser F; Decuman S; Brusselle G; De Pauw M; Deschepper E; De Wilde K; Elewaut D; Piette Y; Vandecasteele E; Smith V
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):148-151. PubMed ID: 27463733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.
    Showalter K; Spiera R; Magro C; Agius P; Martyanov V; Franks JM; Sharma R; Geiger H; Wood TA; Zhang Y; Hale CR; Finik J; Whitfield ML; Orange DE; Gordon JK
    Ann Rheum Dis; 2021 Feb; 80(2):228-237. PubMed ID: 33028580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling.
    Baron M; Barbacki A; Man A; de Vries-Bouwstra JK; Johnson D; Stevens W; Osman M; Wang M; Zhang Y; Sahhar J; Ngian GS; Proudman S; Nikpour M;
    Rheumatology (Oxford); 2023 Sep; 62(9):3059-3066. PubMed ID: 36625513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.